Medscape InDiscussion: Schizophrenia
Een podcast door Medscape
12 Afleveringen
-
S2 Episode 6: Is MDMA a Potential Treatment for Negative Symptoms of Schizophrenia? Exploring Stigma and Strategies to Alleviate Symptoms
Gepubliceerd: 20-7-2023 -
S2 Episode 5: First-Episode Schizophrenia: The Importance of Engaging and Educating Patients and Their Families in Treatment
Gepubliceerd: 21-6-2023 -
S2 Episode 4: Common and Commonly Unrecognized: Clinical High-risk Syndrome, Psychosis, and Schizophrenia
Gepubliceerd: 23-5-2023 -
S2 Episode 3: Psychiatric Comorbidity in Schizophrenia: Assessing Patients and the Impact on Treatment Decisions and Outcomes
Gepubliceerd: 19-4-2023 -
S2 Episode 2: Long-Acting Injectables and Schizophrenia: Mitigating the Risk for Relapse and Rehospitalization
Gepubliceerd: 22-3-2023 -
S2 Episode 1: Treatment-Resistant Schizophrenia: Detection, Management, and the Importance of Early Initiation of Treatment
Gepubliceerd: 22-3-2023 -
S1 Episode 6: Relapse in Schizophrenia: Why It Occurs, How Often It Occurs, and What We Can Do About It
Gepubliceerd: 7-12-2022 -
S1 Episode 5: Neuroimaging in Schizophrenia: What Have We Learned?
Gepubliceerd: 9-11-2022 -
S1 Episode 4: How Can We Assess Cognitive Functioning in Patients With Schizophrenia? And What Can We Do About It?
Gepubliceerd: 5-10-2022 -
S1 Episode 3: What New Antipsychotic Drugs Are Available for Schizophrenia? What Drugs Are Under Development? And What Do They Potentially Offer?
Gepubliceerd: 13-9-2022 -
S1 Episode 2: Antipsychotics in Schizophrenia: Effectiveness and Optimal Dosing
Gepubliceerd: 2-8-2022 -
S1 Episode 1: What Are the Major Metabolic and Neurologic Risks Associated With Antipsychotic Medications?
Gepubliceerd: 2-8-2022
1 / 1
Listen to Medscape InDiscussion: Schizophrenia, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984480). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
